Although antibody targeting of TNF-R1 as cancer therapy seems promising due to its proinflammatory signaling [96], diverse TNF-R1 antagonist antibodies (e.g., Atrosab) have been designed as treatment of rheumatoid arthritis (RA) and multiple sclerosis, among other autoimmune diseases [97,98]. This evidence concerns the gene TNFRSF1A and multiple sclerosis.